PARP1 and hypoparathyroidism-retardation-dysmorphism syndrome: As described above, HR deficiency (HRD) is a predictor of PARP inhibitor efficacy and PARP inhibitors are particularly cytotoxic in tumors displaying mutations in BRCA1/2.